Atlas Trials

ArriVent BioPharma, Inc.

5 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch ArriVent BioPharma, Inc.

RecordFirmDate
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. (NCT07755436)ArriVent BioPharma, Inc.2026-07-23
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (NCT07185997)ArriVent BioPharma, Inc.2025-12-17
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors (NCT07066657)ArriVent BioPharma, Inc.2025-07-25
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) (NCT05607550)ArriVent BioPharma, Inc.2023-06-01
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations (NCT05364073)ArriVent BioPharma, Inc.2022-06-30

Track ArriVent BioPharma, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.